Abstract | OBJECTIVES: METHODS: Genotypes were determined for several genes involved in serotonergic pathway in 51 children with FXS, ages 24-72months. Correlations between genotypes and deviations from baseline in primary and secondary outcome measures were modeled using linear regression models. RESULTS: A significant association was observed between a BDNF polymorphism and improvements for several clinical measures, including the Clinical Global Impression scale (P=0.008) and the cognitive T score (P=0.017) in those treated with sertraline compared to those in the placebo group. Additionally, polymorphisms in the MAOA, Cytochrome P450 2C19 and 2D6, and in the 5-HTTLPR gene showed a significant correlation with some of the secondary measures included in this study. CONCLUSION: This study shows that polymorphisms of genes involved in the serotonergic pathway could play a potential role in predicting response to sertraline treatment in young children with FXS. Larger studies are warranted to confirm these initial findings.
|
Authors | Reem Rafik AlOlaby, Stefan R Sweha, Marisol Silva, Blythe Durbin-Johnson, Carolyn M Yrigollen, Dalyir Pretto, Randi J Hagerman, Flora Tassone |
Journal | Brain & development
(Brain Dev)
Vol. 39
Issue 6
Pg. 483-492
(Jun 2017)
ISSN: 1872-7131 [Electronic] Netherlands |
PMID | 28242040
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Biomarkers
- Brain-Derived Neurotrophic Factor
- SLC6A4 protein, human
- Serotonin Plasma Membrane Transport Proteins
- Serotonin Uptake Inhibitors
- Cytochrome P-450 Enzyme System
- Monoamine Oxidase
- monoamine oxidase A, human
- Matrix Metalloproteinase 9
- Sertraline
|
Topics |
- Autism Spectrum Disorder
(drug therapy, genetics)
- Biomarkers
(metabolism)
- Brain-Derived Neurotrophic Factor
(blood)
- Child
- Child, Preschool
- Cohort Studies
- Cytochrome P-450 Enzyme System
(genetics, metabolism)
- Double-Blind Method
- Female
- Fragile X Syndrome
(blood, drug therapy, genetics)
- Genotype
- Humans
- Male
- Matrix Metalloproteinase 9
(metabolism)
- Monoamine Oxidase
(genetics, metabolism)
- Serotonin Plasma Membrane Transport Proteins
(genetics, metabolism)
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Sertraline
(therapeutic use)
- Severity of Illness Index
|